These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 4794963)

  • 1. Injection method for delivery of long-acting narcotic antagonists.
    Leafe TD; Sarner SF; Woodland JH; Yolles S; Blake DA; Meyer FJ
    Adv Biochem Psychopharmacol; 1973; 8(0):569-75. PubMed ID: 4794963
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-acting delivery systems for narcotic antagonists. 1.
    Woodland JH; Yolles S; Blake DA; Helrich M; Meyer FJ
    J Med Chem; 1973 Aug; 16(8):897-901. PubMed ID: 4745832
    [No Abstract]   [Full Text] [Related]  

  • 3. Design consideration for long-acting antagonists.
    Archer S
    Adv Biochem Psychopharmacol; 1973; 8(0):549-53. PubMed ID: 4368570
    [No Abstract]   [Full Text] [Related]  

  • 4. Biocompatible implants for the sustained zero-order release of narcotic antagonists.
    Abrahams RA; Ronel SH
    J Biomed Mater Res; 1975 May; 9(3):355-66. PubMed ID: 1176491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of sustained action preparations of narcotic antagonists.
    Willette RE
    NIDA Res Monogr; 1976 Sep; (9):31-4. PubMed ID: 1004531
    [No Abstract]   [Full Text] [Related]  

  • 6. Background on animal testing in the drug delivery systems program.
    Dewey WL
    NIDA Res Monogr; 1981; 28():69-76. PubMed ID: 6791014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Narcotic antagonists: the search for long-acting preparations: introduction.
    Willette RE
    Natl Inst Drug Abuse Res Monogr Ser; 1975; (4):1-5. PubMed ID: 827708
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-acting parenteral drug formulations.
    Chien YW
    J Parenter Sci Technol; 1981; 35(3):106-39. PubMed ID: 6113276
    [No Abstract]   [Full Text] [Related]  

  • 9. Long acting delivery systems for narcotic antagonists II: release rates of naltrexone from poly(lactic acid) composites.
    Yolles S; Leafe TD; Woodland JH; Meyer FJ
    J Pharm Sci; 1975 Feb; 64(2):348-9. PubMed ID: 1127596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Application of cyclazocine in modified neuroleptanesthesia].
    Niiya S; Hirano K; Hara K; Miyoshi Y; Yukinari T; Itohda Y; Haseba S; Gotoh Y; Nakamura H
    Masui; 1983 Mar; 32(3):310-5. PubMed ID: 6864995
    [No Abstract]   [Full Text] [Related]  

  • 11. Insoluble salts and salt complexes of cyclazocine and naloxone.
    Gray AP; Robinson DS
    Adv Biochem Psychopharmacol; 1973; 8(0):555-68. PubMed ID: 4800171
    [No Abstract]   [Full Text] [Related]  

  • 12. In vivo and in vitro evaluation of a microencapsulated narcotic antagonist.
    Mason N; Thies C; Cicero TJ
    J Pharm Sci; 1976 Jun; 65(6):847-50. PubMed ID: 932970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Principles of retardation].
    Hüttenrauch R
    Pharmazie; 1975 Jan; 30(1):3-16. PubMed ID: 1094473
    [No Abstract]   [Full Text] [Related]  

  • 14. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
    Dunbar JL; Turncliff RZ; Dong Q; Silverman BL; Ehrich EW; Lasseter KC
    Alcohol Clin Exp Res; 2006 Mar; 30(3):480-90. PubMed ID: 16499489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long acting porous microparticle for pulmonary protein delivery.
    Kwon MJ; Bae JH; Kim JJ; Na K; Lee ES
    Int J Pharm; 2007 Mar; 333(1-2):5-9. PubMed ID: 17296275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Withdrawal programmes for narcotics addicts in the USA].
    Neudek K
    Munch Med Wochenschr; 1970 May; 112(22):1054-6. PubMed ID: 4987316
    [No Abstract]   [Full Text] [Related]  

  • 17. Narcotic antagonists in the treatment of opiate dependence.
    Fink M; Zaks A; Resnick RB; Freedman AM
    Int Z Klin Pharmakol Ther Toxikol; 1971 Jun; 4(4):455-8. PubMed ID: 5566728
    [No Abstract]   [Full Text] [Related]  

  • 18. An improved long-acting delivery system for narcotic antagonists.
    Misra AL; Pontani RB
    J Pharm Pharmacol; 1978 May; 30(5):325-6. PubMed ID: 26754
    [No Abstract]   [Full Text] [Related]  

  • 19. Viscosity of polymer solution phase and other factors controlling the dissolution of theophylline microspheres prepared by the emulsion solvent evaporation method.
    Obeidat WM; Price JC
    J Microencapsul; 2003; 20(1):57-65. PubMed ID: 12519702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral and morphine-antagonist effects of the optical isomers of pentazocine and cyclazocine.
    McMillan DE; Harris LS
    J Pharmacol Exp Ther; 1972 Mar; 180(3):269-79. PubMed ID: 5012778
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.